title: The effects of montelukast on intradermal wheal and flare.
abstract: OBJECTIVE
  We sought to determine the effect of montelukast, a leukotriene receptor antagonist, on intradermal skin testing. Study design and setting We conducted a prospective, randomized, double-blind, placebo-controlled study in a university setting.
  
  
  METHODS
  After a 1-week washout of allergy pharmacotherapy, intradermal skin testing was performed on 23 atopic subjects. Whealing size was measured 20 minutes after injection. Subjects then began a 1-week regimen of daily loratadine, montelukast, or placebo. At 1 week, subjects again underwent intradermal skin testing. The change in wheal size was then calculated from baseline.
  
  
  RESULTS
  A significant difference (P < 0.05) between the montelukast and loratadine groups in suppression of intradermal whealing at 1 week was observed. No significant difference was noted between the montelukast and placebo subjects.
  
  
  CONCLUSIONS
  Montelukast demonstrated no significant suppression of skin whealing after antigen challenge over placebo.
  
  
  CONCLUSIONS
  Montelukast does not need to be discontinued before intradermal allergy testing.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Wayne State University, Detroit, Michigan 48201, USA.
authors.forename: Samuel L
authors.initials: SL
authors.lastname: Hill
authors.forename: John H
authors.initials: JH
authors.lastname: Krouse
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D002176:Candida albicans / Q000276:immunology; D003521:Cyclopropanes; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006632:Histamine / Q000276:immunology; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology; D007271:Injections, Intradermal; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D017336:Loratadine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis*; D012882:Skin Tests / Q000009:adverse effects*; D013440:Sulfides
chemical_list: D000085:Acetates; D018926:Anti-Allergic Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D017336:Loratadine; D006632:Histamine; C093875:montelukast